Video

VIDEO: Treating heart failure congestion improved hyperglycemia


 

EXPERT ANALYSIS FROM ACC 15

References

SAN DIEGO – Congestion secondary to advanced heart failure appears to cause type 2 diabetes in a significant subgroup of patients, based on suggestive findings from a series of recently reported studies, Dr. Maya Guglin said during an interview at the annual meeting of the American College of Cardiology.

Dr. Guglin reviewed convergent findings from several groups of patients who received left ventricular assist devices to treat advanced heart failure. The analyses all showed that many, though not a majority, of those patients also had type 2 diabetes. Soon after patients received an assist device, the type 2 diabetes uniformly improved – and in many cases, glycemic control normalized.

Dr. Guglin, who has named this condition “cardiogenic diabetes,” said that reducing congestion with an assist device or with diuretic treatment seems the best way to both reduce congestion and improve or resolve the diabetes.

Those treatments will “improve quality of life, reduce hospital admissions for heart failure, and also improve the course of diabetes,” said Dr. Guglin, professor of medicine and medical director of the ventricular assist device program at the University of Kentucky in Lexington.

Dr. Guglin had no disclosures.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Recommended Reading

Ablation cuts AF recurrence 2.5-fold vs. amiodarone in heart failure
MDedge Cardiology
Novel agent fails to reduce infarct size, but may cut heart failure, protect kidneys
MDedge Cardiology
Catheter treatment for PAH outperforms medication
MDedge Cardiology
MOOD-HF: SSRI ineffective in heart failure with depression
MDedge Cardiology
Anticipation runs high for coming megatrials in general cardiology
MDedge Cardiology
LEGACY: Weight loss markedly improves atrial fibrillation
MDedge Cardiology
CoreValve receives first TAVR valve-in-valve indication
MDedge Cardiology
Ventricular gel injections improve advanced heart failure
MDedge Cardiology
Heart failure spurs 'cardiogenic diabetes'
MDedge Cardiology
FDA panel reassured by saxagliptin’s CV safety data
MDedge Cardiology

Related Articles